Hemoglobin A 1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations

Managed Care

Volumn 21, Issue 7, 2012, Pages 40-48

  Williams, Setareh A ^a   Buysman, Erin K ^b   Hulbert, Erin M ^b   Bergeson, Joette Gdovin ^c   Zhang, Bin ^c   Graham, John ^c  

^a ASTRAZENECA   (United Kingdom)

^b OPTUM   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEALTH SERVICE; HUMAN; INSURANCE; MALE; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; UNITED STATES; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SERVICES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84865824909     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (15)

1. American Diabetes Association. http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed December 6, 2010.
2. American Diabetes Association, 2009. Obtained from: http://care.diabetesjournals.org/content/vol32/Supplement_1/. Accessed February 3, 2010. http://care.diabetesjournals.org/content/34/Supplement_1. Accessed February 15, 2011.
3. American Diabetes Association. Executive Summary: Standards of Medical Care on Diabetes - 2010. Diabetes Care 33 Supplement 1; 2010. pp S4-S10.
4. Chalmers J, Kengne AP, Joshi R, Perkovic V, Patel A. New insights from ADVANCE. J Hypertens Suppl. 2007;25:S23-30.
5. Chalmers J, Perkovic V, Joshi R, Patel A. ADVANCE: breaking new ground in type 2 diabetes. J Hypertens Suppl. 2006;24:S22-8.
6. Cheong, C. Patient Adherence and Reimbursement Amount for Antidiabetic Fixed-Dose Combination Products Compared with Dual Therapy Among Texas Medicaid Recipients. Clinical Therapeutics. 2008;30(10)1893-1907.
7. Comorbidity software 2009. Available at: http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.
8. Leinung M, Thompson S, Nardacci E. Benefits of continuous glucose monitor use in clinical practice. Endocr Pract. 2010 May-Jun;16(3):371-5.
9. Maclean JR, Chapman RH, Ferrufino CP, Krishnarajah G. Drug titration patterns and HbA 1c levels in type 2 diabetes. Int J Clin Pract. 2009 Jul;63(7):1008-16.
10. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17(3):283-95.
11. Melikiun, C. Adherence to Oral Antidiabetic Therapy in a Managed Care Organization: A Comparison of Monotherapy, Combination Therapy, and Fixed-Dose Combination Therapy. Clinical Therapeutics. 2002;24(3), 460-67.
12. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA, Coding algorithms for defining comorbidities in ICD-9-CM and ICD- 10 administrative data. Medical Care. 2005;43:1130-39.
13. Rodbard HW, Jellinger PS,, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocr Pract. 2009;15:540-59.
14. UK prospective diabetes study group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
15. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2009, Medical Care. Series ID: SUUR0000SAM. Washington, D.C.: U.S. Dept. of Labor, Bureau of Labor Statistics, 2009. http://data.bls.gov/cgi-bin/surveymost?su